Welcome to our dedicated page for Neurobo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on Neurobo Pharmaceuticals stock.
NeuroBo Pharmaceuticals Inc. (NRBO), now MetaVia Inc., reports developments for a clinical-stage biotechnology business focused on cardiometabolic diseases. Its recurring company updates center on DA-1726, a dual oxyntomodulin analog agonist of GLP-1 and glucagon receptors for obesity, and DA-1241, an oral GPR119 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH.
News items commonly cover clinical trial data, dosing and formulation work, research collaborations, quarterly financial results, corporate presentations, investor-conference activity, and the completed corporate name change from NeuroBo to MetaVia. The updates connect the company's pipeline progress with cash runway commentary, partner relationships, and public-company communications.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced a private placement to raise $10.0 million by issuing 2,500,000 shares at $4.00 per share and associated warrants. The transaction, expected to close on January 21, 2021, will provide funds for working capital and other corporate needs. Each warrant has an exercise price of $6.03 and is exercisable after six months for five and a half years. The company plans to register these shares with the SEC by January 25, 2021.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced its acquisition of ANA Therapeutics on December 31, 2020. This acquisition introduces ANA-001, a niclosamide-based treatment for COVID-19 currently in Phase 2/3 trials. The deal is backed by both companies' boards and aims to expedite the development of this promising therapy via the 505(b)(2) clinical pathway. NeuroBo anticipates key milestones within the next 12-18 months, including data readouts from the ongoing clinical trials.
NeuroBo Pharmaceuticals (NRBO) reported its Q3 2020 financial results, showing a net loss of approximately $3.1 million, or $0.19 per share, an improvement from a $3.6 million loss in Q3 2019. R&D expenses increased slightly to $1.3 million, while G&A expenses decreased to $1.8 million. NeuroBo continues to prepare for an IND application for NB-02 but has postponed clinical trials due to COVID-19, aiming to initiate them in H2 2021. The company has $12.4 million in cash, sufficient to fund operations into Q3 2021.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) announced the appointment of Douglas J. Swirsky to its Board of Directors effective September 1, 2020. Swirsky, who also serves as President and CEO of Rexahn Pharmaceuticals, brings over 20 years of biopharmaceutical experience. He will replace Steven Gullans, Ph.D., who resigned on August 31, 2020. NeuroBo is known for its innovative treatments for neurodegenerative and cardiometabolic diseases, including drug candidates like NB-01 and NB-02. The company continues to navigate the impacts of COVID-19 on its clinical trials.
NeuroBo Pharmaceuticals (NASDAQ: NRBO) reported its Q2 2020 financial results, showing a net loss of approximately $2.4 million or $0.15 per share, compared to a net loss of $1.9 million or $0.37 per share in Q2 2019. R&D expenses decreased to $0.7 million, primarily due to halted Phase 3 trials for NB-01. General and administrative expenses increased to $1.7 million due to public company costs. Cash and cash equivalents were $14.3 million as of June 30, 2020, expected to fund operations into Q2 2021.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) will join the Russell 3000 and Microcap Indexes on June 29, 2020, as part of the annual reconstitution process. This inclusion reflects the company’s market acceptance following its reverse merger with Gemphire Therapeutics in December 2019. The Russell Indexes are used by many investors for benchmarking and investment strategies, managing approximately $9 trillion in assets. NeuroBo focuses on developing therapies for neurodegenerative and cardiometabolic diseases with candidates like NB-01 and NB-02, currently advancing through clinical stages.